ArticleCell cycle (Georgetown, Tex.)2013
Chronic rapamycin treatment or lack of S6K1 does not reduce ribosome activity in vivo.
Article in Cell cycle (Georgetown, Tex.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Calorie restriction and rapamycin distinctly restore non-canonical ORF translation in the muscles of aging mice.NPJ Regenerative medicine · 2024Article
- Inhibition of S6K lowers age-related inflammation and increases lifespan through the endolysosomal system.Nature aging · 2024Article
- Stabilizing Immature Dendritic Spines in the Auditory Cortex: A Key Mechanism for mTORC1-Mediated Enhancement of Long-Term Fear Memories.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023Article
- Mechanistic Target of Rapamycin Complex 1: From a Nutrient Sensor to a Key Regulator of Metabolism and Health.Advances in nutrition (Bethesda, Md.) · 2022Article
- The Translational Regulation in mTOR Pathway.Biomolecules · 2022Review
- Article
- The TOR-dependent phosphoproteome and regulation of cellular protein synthesis.The EMBO journal · 2021Article
- Article
- Transcriptional programming of lipid and amino acid metabolism by the skeletal muscle circadian clock.PLoS biology · 2018Article
- Key proteins and pathways that regulate lifespan.The Journal of biological chemistry · 2017Review
- The role of mTOR signalling in the regulation of skeletal muscle mass in a rodent model of resistance exercise.Scientific reports · 2016Article
- Reduced insulin/insulin-like growth factor signaling decreases translation in Drosophila and mice.Scientific reports · 2016Article
- Inhibition of the Mechanistic Target of Rapamycin (mTOR)-Rapamycin and Beyond.Cold Spring Harbor perspectives in medicine · 2016Review
- Article
- Reduced in vivo hepatic proteome replacement rates but not cell proliferation rates predict maximum lifespan extension in mice.Aging cell · 2016Article
- Molecular studies of exercise, skeletal muscle, and ageing.F1000Research · 2016Review
- Reducing Ribosomal Protein S6 Kinase 1 Expression Improves Spatial Memory and Synaptic Plasticity in a Mouse Model of Alzheimer's Disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015Article
- Alcohol impairs skeletal muscle protein synthesis and mTOR signaling in a time-dependent manner following electrically stimulated muscle contraction.Journal of applied physiology (Bethesda, Md. : 1985) · 2014Article
- Aging is not programmed: genetic pseudo-program is a shadow of developmental growth.Cell cycle (Georgetown, Tex.) · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
Reducing activity of the mTORC1/S6K1 pathway has been shown to extend lifespan in both vertebrate and invertebrate models. For instance, both pharmacological inhibition of mTORC1 with the drug rapamycin or S6K1 knockout extends lifespan in mice. Since studies with invertebrate models suggest that reducing translational activity can increase lifespan, we reasoned that the benefits of decreased mTORC1 or S6K1 activity might be due, at least in part, to a reduction of general translational activity. Here, we report that mice given a single dose of rapamycin have reduced translational activity, while mice receiving multiple injections of rapamycin over 4 weeks show no difference in translational activity compared with vehicle-injected controls. Furthermore, mice lacking S6K1 have no difference in global translational activity compared with wild-type littermates as measured by the percentage of ribosomes that are active in multiple tissues. Translational activity is reduced in S6K1-knockout mice following single injection of rapamycin, demonstrating that rapamycin's effects on translation can occur independently of S6K1. Taken together, these data suggest that benefits of chronic rapamycin treatment or lack of S6K1 are dissociable from potential benefits of reduced translational activity, instead pointing to a model whereby changes in translation of specific subsets of mRNAs and/or translation-independent effects of reduced mTOR signaling underlie the longevity benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.